Revolution Medicines Inc (RVMD)
$38.82
+1.54
(+4.13%)▲
Insights on Revolution Medicines Inc
Decreasing Revenue
Revenue is down for the last 4 quarters, 15.33M → 742.0K (in $), with an average decrease of 60.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 5 quarters, -56.50M → -161.53M (in $), with an average decrease of 32.7% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.0% return, outperforming this stock by 234.7%
Performance
- $37.18$39.47$38.82
4.24%
Downside
Day's Volatility :5.81%
Upside
1.65%
- $15.44$38.82$38.82
60.23%
Downside
52 Weeks Volatility :60.23%
Upside
0.0%
Returns
| Period | Revolution Medicines Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 31.92% | -1.3% | 0.0% |
6 Months | 83.19% | 12.4% | 0.0% |
1 Year | 56.31% | 4.6% | 0.0% |
3 Years | 12.46% | 15.7% | -21.9% |
Highlights
Market Capitalization | 5.9B |
Book Value | $11.09 |
Earnings Per Share (EPS) | -3.86 |
Wall Street Target Price | 41.58 |
Profit Margin | 0.0% |
Operating Margin TTM | -20819.81% |
Return On Assets TTM | -20.08% |
Return On Equity TTM | -34.75% |
Revenue TTM | 11.6M |
Revenue Per Share TTM | 0.1 |
Quarterly Revenue Growth YOY | -95.19999999999999% |
Gross Profit TTM | -217.7M |
EBITDA | -456.7M |
Diluted Eps TTM | -3.86 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.19 |
EPS Estimate Next Year | -3.43 |
EPS Estimate Current Quarter | -0.88 |
EPS Estimate Next Quarter | -0.77 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 7.11%
Technicals Summary
Sell
Neutral
Buy
Revolution Medicines Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Revolution Medicines Inc | 17.68% | 83.19% | 56.31% | 12.46% | 29.0% |
 Moderna, Inc. | 4.46% | 44.76% | -17.31% | -40.7% | 317.84% |
 Regeneron Pharmaceuticals, Inc. | -8.11% | 12.56% | 10.41% | 82.28% | 161.35% |
 Novo Nordisk A/s | 0.6% | 31.36% | 53.28% | 240.62% | 422.33% |
 Vertex Pharmaceuticals Incorporated | -6.58% | 6.36% | 13.86% | 80.23% | 127.58% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Revolution Medicines Inc | NA | NA | NA | -3.19 | -0.35 | -0.2 | NA | 11.09 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Revolution Medicines Inc | Buy | $5.9B | 29.0% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 317.84% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 161.35% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 422.33% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 127.58% | 28.81 | 36.68% |
Institutional Holdings
Wellington Management Company LLP
9.04%Vanguard Group Inc
8.89%BlackRock Inc
7.87%Farallon Capital Management, L.L.C.
4.09%Nextech Invest AG
3.82%State Street Corporation
3.80%
Corporate Announcements
Revolution Medicines Inc Earnings
Revolution Medicines Inc’s price-to-earnings ratio stands at None
Read More
Company Information
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
Organization | Revolution Medicines Inc |
Employees | 378 |
CEO | Dr. Mark A. Goldsmith Ph.D. |
Industry | Health Technology |
Discover More
Sasol Ltd.
$38.82
+4.13%
Dimensional Us Core Equity M
$38.82
+4.13%
Crinetics Pharmaceuticals Inc
$38.82
+4.13%
Tenet Healthcare Corp.
$38.82
+4.13%
Paycor Hcm Inc
$38.82
+4.13%
Icahn Enterprises, L.p.
$38.82
+4.13%
Immunocore Holdings Plc-adr
$38.82
+4.13%
Jpmorgan Betabuilders Us Equ
$38.82
+4.13%
Newmarket Corporation
$38.82
+4.13%